NDAINTRAVENOUSSOLUTIONPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Clinical Trials (3)
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Started Feb 2024
274 enrolled
Prostate Cancer
An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer
Started Feb 2023
500 enrolled
Prostate Cancer
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Started Oct 2022
36 enrolled
Pancreatic CancerBreast CancerHepatocellular Carcinoma
Loss of Exclusivity
LOE Date
Jun 9, 2037
137 months away
Patent Expiry
Jun 9, 2037
Exclusivity Expiry
May 26, 2026